Retrospective analysis of 264 multiple myeloma patients

Oncology Letters

Volumn 5, Issue 2, 2013, Pages 707-713

  Geng, Chuanying ^a   Liu, Nian ^a   Yang, Guangzhong ^a   Liu, Aijun ^a   Leng, Yun ^a   Wang, Huijuan ^a   Li, Lihong ^a   Wu, Yin ^a   Li, Yanchen ^a   Chen, Wenming ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Autologous stem cell transplantation; Bortezomib; Multiple myeloma; Survival

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; EPIRUBICIN; IMMUNOGLOBULIN G; MELPHALAN; PREDNISONE; TETRACYCLINE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CHROMOSOME DELETION; DRUG EFFICACY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

EID: 84871536273     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.1018     Document Type: Article

References (17)

1. Raab MS, Podar K, Breitkreutz I, Richardson PG and AndersonKC: Multiple myeloma. Lancet 374: 324-339, 2009.
2. Rajkumar SV: Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 86: 57-65, 2011.
3. Kyle RA and Rajkumar SV: Multiple myeloma. Blood 111: 2962-2972, 2008.
4. Kyle RA, Gertz MA, Witzig TE, et al: Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc78: 21-33, 2003.
5. Durie BG, Harousseau JL, Miguel JS, et al: International uniform response criteria for multiple myeloma. Leukemia 20: 1467-1473, 2006.
6. Becker N: Epidemiology of multiple myeloma. Recent Results Cancer Res 183: 25-35, 2011.
7. Tuscano JM: Multiple myeloma: epidemiology and therapeutic options. Manag Care 17: 9-15, 2008.
8. Mileshkin L, Biagi JJ, Mitchell P, et al: Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 102: 69-77, 2003.
9. Choi JH, Yoon JH and Yang SK: Clinical value of new staging systems for multiple myeloma. Cancer Res Treat 39: 171-174, 2007.
10. Greipp PR, San Miguel J, Durie BG, et al: International staging system for multiple myeloma. J Clin OncoI 23: 3412-3420, 2005.
11. Avet-Loiseau H, Attal M, Moreau P, et al: Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood 109: 3489-3495, 2007.
12. Gutiérrez NC, Castellanos MV, Martín ML, et al: Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 21: 143-150, 2007.
13. Nadal E, Giné E, Bladé J, et al: High-dose therapy/autologous stem cell transplantation in patients with chemosensitive myeloma: predictors of complete remission. Bone Marrow Transplant 33: 61-64, 2004.
14. Lahuerta JJ, Mateos MV, Martínez-López J, et al: Influence of pre-and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 26: 5775-5782, 2008.
15. van de Velde HJ, Liu X, Chen G, et al: Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 92: 1399-1406, 2007.
16. Delforge M: Bortezomib for previously untreated multiple myeloma. Expert Opin Pharmacother 12: 2553-2564, 2011.
17. Terpos E, Roussou M and Dimopoulos MA: Bortezomib in multiple myeloma. Expert Opin Drug Metab Toxicol 4: 639-654, 2008.